Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps - 2Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
- 3Share your pick for the miniature headphones that you generally suggest!
- 4It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- 5Uncover the Manageable Fish Practices: Sea agreeable Feasting
- A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- Experience Arranging: Planning for Epic Excursions
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- Where You Could Sleep With Snorlax in Japan, From MIMARU’s Pokémon Rooms to Grand Hyatt Tokyo’s Limited Pokémon Suite
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
- The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- Russia patents space station designed to generate artificial gravity
- All that You Really want to Be familiar with Dental Inserts Facilities
- 3 Must-Change Settings for iPhone Clients: Safeguard Yourself !
